Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database - Scorecard - MDSpire
Advertisement
Signal mining of adverse reactions for neuraminidase inhibitors in pregnant women: a disproportionality analysis based on the FDA adverse event reporting system database
Clinical Scorecard: Analysis of Adverse Effects Related to Neuraminidase Inhibitors in Pregnant Women: A Disproportionality Study Utilizing the FDA Adverse Event Reporting System Database
At a Glance
Category
Detail
Condition
Adverse events associated with neuraminidase inhibitors in pregnant women
Key Mechanisms
Utilization of FDA Adverse Event Reporting System (FAERS) database for signal detection
Target Population
Pregnant women receiving neuraminidase inhibitors for influenza treatment
Care Setting
Real-world clinical settings
Key Highlights
remove
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Pregnant women treated with neuraminidase inhibitors
Adverse events do not appear to increase overall risk during pregnancy
A Beyond the Guidelines discussion highlighted uncertainty around gastrointestinal evaluation and intravenous iron use in premenopausal women with iron deficiency.
